


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Previously Presented) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

in which:

X is C₁₋₆alkyl or OR⁶;

Y is selected from hydrogen, halogen, CN, nitro, SO₂R³, OR⁴, SR⁴, SOR³, SO₂NR⁴R⁵, CONR⁴R⁵, NR⁴R⁵, NR⁶SO₂R³, NR⁶CO₂R⁶, NR⁶COR³, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl or C₁₋₆alkyl, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, OR⁶ and NR⁶R⁷, S(O)_nR⁶; n is 0, 1 or 2;

Z is phenyl optionally substituted by one or more substituents independently selected from hydrogen, halogen, CN, OH, SH, nitro, COR⁹, CO₂R⁶, SO₂R⁹, OR⁹, SR⁹, SOR⁹, SO₂NR¹⁰R¹¹,

$\text{CONR}^{10}\text{R}^{11}$, $\text{NR}^{10}\text{R}^{11}$, $\text{NH}\text{SO}_2\text{R}^9$, $\text{NR}^9\text{SO}_2\text{R}^9$, $\text{NR}^6\text{CO}_2\text{R}^6$, NHCOR^9 , NR^9COR^9 , $\text{NR}^6\text{CONR}^4\text{R}^5$, $\text{NR}^6\text{SO}_2\text{NR}^4\text{R}^5$, aryl,

$\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_3\text{-C}_7$ cycloalkyl or C_{1-6} alkyl, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, $\text{C}_3\text{-C}_7$ cycloalkyl, OR^6 , NR^6R^7 , $\text{S}(\text{O})_n\text{R}^6$, CONR^6R^7 , NR^6COR^7 , $\text{SO}_2\text{NR}^6\text{R}^7$ and $\text{NR}^6\text{SO}_2\text{R}^7$.

R^1 and R^2 independently represent a hydrogen atom, halogen, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $\text{C}_3\text{-C}_7$ cycloalkyl or a C_{1-6} alkyl group, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, $\text{C}_3\text{-C}_7$ cycloalkyl, NR^6R^7 , OR^6 , $\text{S}(\text{O})_n\text{R}^6$,

R^3 represents $\text{C}_3\text{-C}_7$ cycloalkyl or C_{1-6} alkyl which may be optionally substituted by one or more substituents independently selected from halogen, $\text{C}_3\text{-C}_7$ cycloalkyl, OR^6 and NR^6R^7 , $\text{S}(\text{O})_n\text{R}^6$, CONR^6R^7 , NR^6COR^7 , $\text{SO}_2\text{NR}^6\text{R}^7$ and $\text{NR}^6\text{SO}_2\text{R}^7$;

R^4 and R^5 independently represent hydrogen, $\text{C}_3\text{-C}_7$ cycloalkyl or C_{1-6} alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen, $\text{C}_3\text{-C}_7$ cycloalkyl, OR^6 and NR^6R^7 , $\text{S}(\text{O})_n\text{R}^6$, CONR^6R^7 , NR^6COR^7 , $\text{SO}_2\text{NR}^6\text{R}^7$ and $\text{NR}^6\text{SO}_2\text{R}^7$;

R^6 and R^7 independently represents a hydrogen atom or C_{1-6} alkyl;

R^8 is hydrogen, C_{1-4} alkyl, $-\text{COC}_{1-4}$ alkyl, $\text{CO}_2\text{C}_{1-4}$ alkyl or $\text{CONR}^6\text{C}_{1-4}$ alkyl;

R^9 represents aryl, $\text{C}_3\text{-C}_7$ cycloalkyl or C_{1-6} alkyl, the latter two groups may be optionally substituted by one or more substituents independently selected from halogen, $\text{C}_3\text{-C}_7$ cycloalkyl, aryl, OR^6 and NR^6R^7 , $\text{S}(\text{O})_n\text{R}^6$, CONR^6R^7 , NR^6COR^7 , $\text{SO}_2\text{NR}^6\text{R}^7$ and $\text{NR}^6\text{SO}_2\text{R}^7$;

R^{10} and R^{11} independently represent aryl, hydrogen, $\text{C}_3\text{-C}_7$ cycloalkyl or

C₁₋₆alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen, C₃-C₇ cycloalkyl, aryl, OR⁶ and NR⁶R⁷, S(O)_nR⁶, CONR⁶R⁷, NR⁶COR⁷, SO₂NR⁶R⁷ and NR⁶SO₂R⁷.

2. (Previously Presented) A compound according to claim 1 in which R¹ and R² independently represent a hydrogen atom, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl or a C₁₋₆alkyl group, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, C₃-C₇ cycloalkyl, NR⁶R⁷, OR⁶, S(O)_nR⁶.
3. (Previously presented) A compound according to claim 1 in which X is C₁₋₄alkyl or C₁₋₄alkoxy.
4. (Previously presented) A compound according to claim 1 in which Y is hydrogen.
5. (Cancelled)
6. (Previously Presented) A compound according to claim 1 in which Z is substituted by one or more substituents independently selected from halogen, C₁₋₃alkyl, cyano and SO₂R⁹.
7. (Previously presented) A compound according to claim 1 in which R¹ and R² are both hydrogen or one is hydrogen and the other is C₁₋₃alkyl.
8. (Previously presented) A compound according to claim 1 selected from:
[(5-Methylbiphenyl-2-yl)oxy]acetic acid,
{[5-Ethyl-4'-(methylsulfonyl)biphenyl-2-yl]oxy}acetic acid,
{[4'-(Ethylsulfonyl)-5-methoxybiphenyl-2-yl]oxy}acetic acid,
[[4-Chloro-4'-(ethylsulfonyl)-2',5'-dimethyl[1,1'-biphenyl]-2-yl]oxy]-acetic acid,
[[4'-(Ethylsulfonyl)-2',5'-dimethyl[1,1'-biphenyl]-2-yl]oxy]-acetic acid,
2-[[3'-Cyano-5-methyl[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,
2-[[2'-Fluoro-5'-cyano-5-methyl[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

and pharmaceutically acceptable salts thereof.

Claims 9-11 (Cancelled)

12. (Currently Amended) A method of treating ~~The method of claim 11, wherein the respiratory disease is~~ asthma or rhinitis, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt as defined in claim 1.

13. (Previously presented) A compound according to claim 2 in which X is C₁₋₄alkyl or C₁₋₄alkoxy.

14. (Previously presented) A compound according to claim 2 in which Y is hydrogen.

15. (Cancelled)

16. (Previously presented) A compound according to claim 2 in which Z substituted by one or more substituents independently selected from halogen, C₁₋₃alkyl, cyano and SO₂R⁹.

17. (Previously presented) A compound according to claim 2 in which R¹ and R² are both hydrogen or one is hydrogen and the other is C₁₋₃ alkyl.

18. (Previously presented) A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, diluent, or carrier.

19. (New) A method of producing a CRTh2 receptor inhibitory effect in a patient, which comprises administering to the patient an effective amount of a compound of formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt thereof.